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Abstract
Influenza is a serious and frequently underestimated, but vaccine pre-
ventable disease. The adamantane derivates rimantadine and
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amantadine and the neuraminidase inhibitors zanamivir and oseltamivir
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are the only antiviral drugs currently approved in Europe for therapy
and prophylaxis of influenza infections. Resistance to these drugs occurs and Other Respiratory
due to mutations within the therapeutic target proteins M2 ion channel Viruses, National Reference
protein and viral neuraminidase. An unexpected occurrence of osel- Centre for Influenza, Berlin,
Germanytamivir-resistant seasonal A(H1N1) viruses was detected in winter
2007/2008. The prevalence of these viruses increased rapidly and
nearby all viruses circulating during the following seasons were resistant
to oseltamivir. The A(H1N1)pdm09 viruses replaced the former seasonal
A(H1N1) subtype during the 2009–2010 influenza season. Fortunately,
resistance to neuraminidase inhibitors was detected in A(H1N1)pdm09,
A(H3N2) and influenza B viruses only sporadically and was treatment
related mostly. Comprehensive analyses of circulating viruses showed
a high prevalence of A(H3N2) influenza viruses that are resistant to
adamantane derivates since 2004/2005 and a progressive trend in
the prevalence of resistant viruses up to 100% in following seasons.
The M2 ion channel protein of A(H1N1)pdm09 viruses is associated
with the Eurasian avian-like swine lineage and thus show “natural”
resistance to adamantane derivates. Therefore, only neuraminidase
inhibitors are recommended for influenza treatment today.
This manuscript summarizes the occurrence and spread of antiviral
resistant influenza viruses and highlights the importance for developing
and/or approving new antiviral compounds.
Keywords: infection, antiviral resistance, neuraminidase, surveillance,
monitoring
1 Fundamental knowledge
Influenza viruses belong to the family Orthomyxoviridae
that is characterized by the ability to attach on glycopro-
teins of host cell surfaces and a segmented genome
composed of single stranded, negatively orientated ribo-
nucleic acid (–ssRNA). Based on their molecular features
and serological characteristics of their nucleoproteins
and matrix proteins influenza viruses are divided into
three genera: Influenzavirus A, Influenzavirus B and Influ-
enzavirus C [1]. Whereas infections with influenza C vir-
uses are often symptomless in humans, influenza A and
B viruses cause annual epidemics known as seasonal
flu, and influenza A viruses also cause pandemics at
random intervals [2].
Influenza A viruses are zoonotic pathogens that can infect
a broad range of species including birds, pigs and hu-
mans. According to the antigenic properties of their sur-
face glycoproteins hemagglutinin (HA) and neuraminidase
(NA) influenza A viruses are further divided into 18 HA
and 11 NA subtypes (H1–H16 and N1–N9 in wild water-
fowl, H17, H18 and N10, N11 in bats) [3]. In comparison
to influenza A viruses influenza B viruses are less variable.
They are antigenically related to either B/Victoria/2/87
or B/Yamagata/16/88 and are distinguished into two
lineages which are referred to as the Yamagata and the
Victoria lineage [4].
The life cycle of the influenza virus begins with binding
of the virus particles to the surface of the host cells.
Binding is mediated by the interaction of viral hemagglu-
tinin (HA) with sialyloligosaccharides on proteins and lipids
of the cell membranes. Due to receptor-mediated endo-
cytosis the virus is internalized into the host cell enclosed
by an endosome. Triggered by low pH in late endosomes
and mediated by M2 ion channel, a conformational
change of HA induces the fusion of the viral and the en-
dosomalmembrane. This triggers the release of uncoated
viral ribonucleoprotein (vRNP) complexes into the cytosol
of the host cell cytoplasm. After transport of vRNP com-
plexes into the nucleus, replication and transcription fol-
lows the amplification of vRNA and synthesis of mRNAs
for viral protein synthesis. Newly assembled vRNPs are
exported to the cytoplasm and assembled with viral pro-
teins at budding sites within the host cell membrane,
followed by the budding and, after cleavage by
neuraminidase, release of influenza virions [2].
Minor changes in viral proteins (antigenic-drift) are caused
by high genomic variability of influenza viruses. Due to
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the lack of a proof-reading activity of the viral polymerase
point mutations in the vRNA occur that might result in
amino acid exchanges of the antigenic epitopes of the
HA and NA proteins. This worsens the recognition and
neutralization (abolishment of infectivity) of influenza
viruses by the host’s immune system antibodies and thus
may lead to immune evasive virus variants. Antigenic-drift
is the cause for influenza epidemics by weakening the
original bond between antigen and antibodies produced
by vaccination, or infection induced immunity.
Antigenic shift results from a reassortment between at
least two influenza subtypes resulting in a new influenza
subtype. This may generate a novel virus able to infect
the majority of the population due to their lack of im-
munity towards the unknown pathogen leading to high
infection rates and pandemic spreads [3], [5]. Both
mechanisms, point mutations as well as reassortment,
can affect the efficacy of anti-influenza drugs.
Influenza occurs globally with an estimated annual attack
rate of 5–10% in adults and 20–30% in children. Both
influenza A and influenza B viruses cause seasonal epi-
demics and out-of-season sporadic cases and outbreaks
[6]. A typical influenza is marked by sudden onset of fever
(≥38.5°C), dry cough, sore throat, body aches and pains,
and headaches. Other symptoms may include general
fatigue, sweating, rhinorrhea, but also nausea, vomiting,
and diarrhea. In more severe cases, infection can lead
to pneumonia, bacterial superinfection and even death.
Nevertheless, not all patients fall ill with typical sympto-
matology. The duration of the disease is usually 5–7 days,
which can be considerably longer depending on compli-
cations and risk factors [7].
Influenza is a vaccine preventable disease and influenza
vaccines have been available for use in Europe since the
1960s. Currently most influenza vaccines contain three
different influenza strains (trivalent): two influenza A
strains (A(H1N1) and A(H3N2) subtypes) and one influ-
enza B strain (Victoria or Yamagata lineage). Starting from
the influenza season 2014–2015 new quadrivalent
combination vaccines containing four different influenza
strains are increasingly becoming available in the
European Union/European Economic Area (EU/EEA).
These vaccines contain two influenza A strains (A(H1N1)
and A(H3N2) subtypes) and two influenza B strains (Vic-
toria and Yamagata lineages) [8]. Annual vaccinations
with the current antigen combination are recommended
by WHO even when the antigen composition of the vac-
cine is unchanged compared with the previous season
[6]. In Germany, the Standing Committee on Vaccination
(STIKO) recommends annual vaccination in autumn as a
standard vaccination for all persons aged 60 years and
older, and where indicated in specific groups of persons
e.g. children, adolescents and adults with an increased
health risk resulting from an underlying disease, all
pregnant women, persons at increased risk, e. g., medical
personnel, persons in establishments dealing extensively
with the public, as well as persons who may be possible
sources of infection by caring for individuals at particular
risk [9].
2 Currently available influenza
medications
In Germany prescription medicines from two classes of
active substances are approved for prevention and ther-
apy of influenza infection (Table 1). The M2 ion channel
inhibitor amantadine belongs to the group of adaman-
tanes and blocks the release of viral RNA into the cyto-
plasm of the host cell. This effect is achieved with thera-
peutic dosage of the active substance only with influenza
A not with influenza B viruses because of different struc-
ture of the ion channel in both influenza species [10].
Due to the current resistance patterns of circulating vir-
uses, the clinical use of adamantanes is not recommend-
ed presently (refer section 6). Thus, amantadine is cur-
rently not used for the treatment of influenza infections.
The compounds oseltamivir (Tamiflu™) and zanamivir
(Relenza™) belong to the group of neuraminidase inhibi-
tors and were approved and authorized by the European
Medicines Agency (EMA) for prevention and treatment of
influenza in the European Union/European Economic
Area (EU/EEA) in 2002 and 1999 [11], [12]. They inhibit
selectively the neuraminidase of influenza A and B vi-
ruses. Thus, the release of new viruses from infected cells
is prevented.
Oseltamivir is admitted by EMA for adults and children
including full-term newborns. It represents a prodrug and
is available as oseltamivir phosphate in the form of cap-
sules and as a powder for oral suspension. The compound
is biotransformed by esterases in the intestinal tract and
in the liver into the active metabolite oseltamivir
carboxylate. The most common possible side effects in-
clude nausea, vomiting and headache. Antiviral therapy
in neonates and young infants (<3 months) should be
considered after careful risk assessment in severe clinical
disease and should follow the recommendations of the
German Society of Pediatric Infectious Diseases (DGPI)
[11], [13].
Zanamivir showed unsatisfactory oral bioavailability and
was therefore mixed with lactose and inhaled as a dry
powder. Undesirable side effects are headache, diarrhea,
nausea, and vomiting. Zanamivir is approved by EMA for
treatment and prevention of influenza infections in pa-
tients from five years old. EMA issued in 2011 a summary
on compassionate use for intravenous (i.v.) zanamivir in
a specific targeted population and should be considered
only to treat i.v. critically ill adults and children having a
life-threatening condition [12], [14], [15].
In 2014 the neuraminidase inhibitors oseltamivir and
zanamivir have been subject for critically discussion
concerning their effectiveness and safety, as well as the
appropriateness of stockpiling these drugs for use in fu-
ture influenza pandemics [16], [17], [18], [19], [20]. An
expert opinion from the European Center for Disease
Prevention and Control (ECDC) and national authorities
as well as national professional virological, medical and
therapeutical associations (GfV e.V., DVV e.V, PEG e.V)
confirmed earlier assessments that there is no significant
2/10GMS Infectious Diseases 2017, Vol. 5, ISSN 2195-8831
Duwe: Influenza viruses – antiviral therapy and resistance
Table 1: List of anti-influenza drugs recently approved or under clinical trials
new evidence from randomized control trials to support
any changes to the approved indication and recommend-
ed use of neuraminidase inhibitors in EU/EEA Member
States. This position was consistent with guidance from
theWorld Health Organization (WHO) and other national
public health organizations in the United States and
Australia [21], [22], [23], [24].
Peramivir (USA: Rapivab™, Japan: Rapiacta™, South
Korea: PeramiFlu™) is a cyclopentane neuraminidase
inhibitor of influenza type A and type B viruses, which in-
hibits also various antiviral resistant influenza viruses.
Due to its poor oral bioavailability peramivir was de-
veloped as intramuscular (i.m.) or intravenous (i.v.) appli-
cable active substance. Themost common adverse reac-
tion is diarrhea [25], [26]. During the pandemic in 2009
peramivir was admitted in the USA based on an emer-
gency use authorization (EUA) by the U. S. Food and Drug
Administration (FDA) until June 23, 2010. On December
19, 2014 the FDA approved also peramivir for treatment
of acute uncomplicated influenza in patients 18 years or
older who have been symptomatic for more than two
days. It is administered as a single i.v. dose [27]. In Japan
and South Korea peramivir injection is approved since
2010 for the treatment of adults, children and infants
with influenza [28].
Laninamivir octanoate (Japan: Inavir®) the octanoyl ester
prodrug of laninamivir represents a zanamivir analogue.
It is a long acting neuraminidase inhibitor (LANI) with
therapeutic efficacy after one single nasal inhaled admin-
istration. Following inhalation laninamivir octanoate is
absorbed by the epithelial cells lining the respiratory tract
where it is rapidly hydrolyzed to the active laninamivir
[29], [30], [31]. Laninamivir was approved for influenza
treatment in 2010 and for prevention of influenza both
in adults and children in 2013 in Japan [32].
T-705 (Favipiravir, Avigan™) represents a prodrug for oral
administration. It selectively inhibits a broad-sprectrum
of RNA-dependent RNA polymerases and thus inhibits
the viral gene replication of influenza viruses and nine
other RNA virus families [33], [34]. The activemetabolite,
T-705 ribofuranosyltriphosphate (T-705RTP) is generated
intracellularly via phosphorylation by various cellular
kinases [35]. The incorporation of T-705RTP into viral
RNA during replication leads to a high mutation rate that
generates a nonviable viral phenotype (lethal mutagenes-
is) [36]. Since March 2014 favipiravir is only approved
for influenza pandemic preparedness in Japan [37].
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All currently approved drugs for influenza prophylaxis and
therapy (ion channel blocker, neuraminidase and poly-
merase inhibitors) are so-called direct acting drugs (DAD).
In contrast, DAS181 (Fludase™), administered as an in-
halable dry powder, is a broad spectrum host directed
investigational influenza antiviral. It is being developed
as a medication to prevent and treat infections due to
common respiratory viruses like influenza, parainfluenza,
and other viruses using cell surface sialic acids as recep-
tors during attachment. Generated as a recombinant fu-
sion protein composed of a sialidase catalytic domain
derived from Actinomyces viscosus fused with a cell sur-
face-anchoring sequence, it cleaves the linkages of sialic
acid on host cells thereby removing the receptors for viral
attachment [38]. This renders the cells inaccessible to
infection by virus. It has also demonstrated activity in in-
dividual cases of parainfluenza in immunosuppressed
patients [39]. The affect on viral load of influenza viruses
and the safety and tolerability of the drug is currently
being evaluated in phase 2 clinical trials in the USA [40].
3 Influenza antiviral resistance
testing
Resistance to antiviral drugs is caused by subtype and
inhibitor specific point mutations in the viral genes of the
therapeutic target proteins. To date, no resistance was
detected for the polymerase inhibitor T-705 until now. In
contrast, ion channel blocker- and neuraminidase inhib-
itor-resistant influenza viruses with point mutations in
gene segments coding for the M2 ion channel and
neuraminidase, respectively, are known. Thesemutations
can be detected by sequence-based technologies (clas-
sical sequencing, pyrosequencing) or, by the use of e.g.
RT-PCR or melting point analysis of specific PCR amplifi-
cation products (genotypic resistance analysis) [41], [42],
[43], [44], [45]. These genotypic assays are advantageous
as they can be performed with high sensitivity directly on
the clinical specimen without the need for virus isolation.
But, estimation of in vitro resistance to inhibitors on the
basis of genotypic profiles is only reliable when the corre-
lation between the presence of a specific point mutation
and drug susceptibility of influenza viruses was proven.
Such amutation represents amolecular marker of resist-
ance. In case of M2 ion channel blockers five molecular
markers of resistance are known [46]. In contrast, inmost
cases estimation of in vitro resistance to neuraminidase
inhibitors on the basis of genotypic profiles is unreliable,
because currently insufficient amount of data are present
to correlate between the presence of molecular marker
of resistance and an actual in vitro resistance marked by
an increase of the 50%-inhibitory concentration (IC50).
Mutations causing the NA H275Y substitution (N1 num-
bering, subtypes A(H1N1)pdm09 and A(H5N1)) are the
only ones consistently associated with increased levels
of IC50-values to oseltamivir detected in NA inhibition as-
says (phenotypic resistance).
The genotypic resistance analysis is considered the gold
standard for M2 ion channel blockers, but phenotypic
resistance analysis represents the gold standard for NAI
(Table 2) [47]. It measures the inhibition of viral
neuraminidase activity and can be carried out by colori-
metric, fluorometric or luminometric neuraminidase inhi-
bition assays [48], [49]. Cell-based assaysmeasuring the
inhibition of viral replication are not recommended for
NA inhibitor susceptibility testing, because they have been
shown to lack sensitivity and reliability, and can give
falsely high or low IC50 values [47], [50], [51]. All pheno-
typic methods require cultured virus but allow the deter-
mination of 50% inhibitory concentration, i.e. that concen-
tration of active compound required to inhibit enzyme
activity by 50%. TheWHOexpert working group on surveil-
lance of influenza antiviral susceptibility (WHO antiviral
working group, AVWG) has established a set of criteria to
define the antiviral susceptibility of viruses based on the
fold-change of their IC50 value compared to reference IC50
values. For influenza A viruses, use of normal (<10-fold
increase), reduced (10–100-fold increase) and highly
reduced (>100-fold increase) inhibition, and for influenza
B viruses the same criteria but using <5-fold, 5–50-fold
and >50-fold increases compared to the median for vir-
uses from the same type/subtype/lineage showing ‘nor-
mal inhibition’ (NI), is recommended. A reduced suscep-
tibility to NA inhibitors measured in phenotypic assays
should be verified by the detection of the associated
molecular resistance marker [52]. Generally, the clinical
relevance of the resistance detected using the NA inhibi-
tion assay in combination with genotypic analysis needs
to be further evaluated. The IC50 values should not be
used to draw a direct correlation with the drug concentra-
tions needed to inhibit virus replication in the infected
human host, as clinical data to support such inferences
are inadequate. Although, assessment of influenza virus
susceptibility to NA inhibitors provides a reliable and
reasonably comprehensive approach to the identification
of NA inhibitor-resistant isolates for surveillance purposes,
there is a pressing need to establish a clinically relevant
IC50 cutoff value which could be used to differentiate
statistical outliers from truly resistant viruses [52], [53].
4 Quality assurances of testing and
monitoring antiviral susceptibility
of influenza viruses
The implementation of genotypic and/or phenotypic tests
for antiviral susceptibility is complex and the laboratory
expertise required for validation and troubleshooting
should be considered. Especially for neuraminidase inhi-
bition assays, although some are commercially available
(NA-Fluor, NA-Star, NA-XTD; Life Technologies), additional
training is likely to be necessary [47], [49]. The use of
genotypic methods also requires a good working know-
ledge of the encoded NA amino acid substitutions, known
to confer reduced susceptibility to antivirals in specific
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Table 2: Influenza antiviral resistance testing
influenza virus types and subtypes [47]. The standard
operation protocols for in house NA inhibition assays
provided from WHO addressed mainly the National Influ-
enza Centres (NICs) but are also available for clinical
laboratories interested in influenza antiviral resistance
testing [54]. However, there is a strongly recommenda-
tion, that individual results of antiviral susceptibility test-
ing in clinical laboratories should be collected nationally
at the NIC [55].
The external quality assessment (EQA) exercise held for
European influenza reference laboratories in 2011 has
identified the need for harmonization antiviral suscepti-
bility testing and data interpretation. Although interpreta-
tion of the data generally matched the consensus, only
85% of participants identified oseltamivir reduced sus-
ceptibility/resistance in a mixture of A(H1N1)pdm09 os-
eltamivir-sensitive/-resistant viruses and 23% considered
oseltamivir-sensitive influenza B virus reduced suscep-
tible/resistant [56]. The external quality assessment for
influenza antiviral susceptibility for the European Refer-
ence Laboratory Network for Human Influenza (ERLI-Net)
held two years later in 2013 showed that compared to
2010 the score improved, although in total only 85% of
the oseltamivir results and for zanamivir 73% of results
were correct [57].
When deciding whether implementation of antiviral sus-
ceptibility testing within a laboratory is practical together
with the long-term costs and the requirements for testing,
a training of laboratory staff in implementation and vali-
dation, troubleshooting, data analysis and interpretation
should be considered. This is often best delivered through
one-to-one training by a partner laboratory (referred to
as “twinning”) [47], [56].
5 Monitoring of antiviral
susceptibility of influenza viruses
in Germany
Worldwide, except Europe, antiviral surveillance data
were mainly reported via theWHO Collaboration Centres
(WHOCC). In Europe antiviral resistance is monitored by
the European Centre for Disease Prevention and Control
(ECDC) and the WHO/Europe Influenza Surveillance
(EuroFlu) based on the reports sent by influenza reference
laboratories (NIC) to The ECDC Surveillance System
(TESSy). In Germany, circulating influenza viruses were
tested in the national influenza centre (NRZ Influenza;
http://www.rki.de/DE/Content/Infekt/NRZ/Influenza/
arbeitsbereiche/abeitsbereiche_node.html) for their an-
tiviral susceptibility on a large scale by using genotypic
and phenotypic methods, thus emergence and spread of
resistant influenza viruses weremonitored. The data were
reported weekly to TESSy and additionally published via
the weekly and seasonally reports of the Working Group
Influenza (AGI; https://www.influenza.rki.de). The exam-
ination of a representative number of influenza A and in-
fluenza B viruses circulating in Germany between October
1998 and May 2016 yielded a resistance situation com-
parable with other countries worldwide.
6 Resistance of influenza viruses
to adamantane derivates
Resistance to the adamantane derivates amantadine
and rimantadine can emerge rapidly during treatment. A
prevalence of <1% was observed in circulating viruses
until 2004. During the influenza season 2004–2005 a
high prevalence and a strong spreading of community
A(H3N2) isolates resistant to adamantaneswere detected
in Asia, Europe, Australia and the USA [58]. In the follow-
ing winter 2005–2006 the prevalence of these viruses
increased to nearly 100% [59]. These findings and the
first reports on the detection of resistant seasonal
A(H1N1) viruses rendered this class of drugsmostly inef-
fective [60]. In response, the CDC recommended against
the use of adamantane derivates for treatment and pre-
vention of influenza infections [61]. In Germany, the
prevalence of primary resistance of A(H3N2) viruses to
adamantane derivates was 12% during the 2004–2005
season. Resistance increased to 81% during the following
winter 2005–2006. Very high frequency of resistant
A(H3N2) viruses continued to be detected, with 100% in
the 2007–2008 influenza season [62]. The resistance-
associated S31N substitution (serine-to-asparagine) of
the M2 ion channel protein (AGT→AAT) was the most
commonly observedmutation [63]. In Germany, all tested
A(H1N1) viruses remained sensitive to amantadin and
rimantadin [62]. In the northern hemisphere increased
prevalence of resistance among A(H1N1) viruses also
has been observed, although the overall proportion of
resistant A(H1N1) viruses was not as high as that for
A(H3N2) viruses until 2009 [59]. The appearance of in-
fluenza viruses of subtype A(H1N1)pdm09 led to a pan-
demic in 2009, followed by complete A(H1N1) subtype
replacement. Due to reassortment (antigenic shift) the
A(H1N1)pdm09 viruses carry theM2 ion channel protein
originated from the Eurasian avian-like swine lineage
[64]. Viruses that are associated with this lineage possess
the M2-S31N substitution as a polymorphism, and show
thus “natural” resistance to adamantane derivates [65],
[66].
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7 Resistance of influenza viruses
to neuraminidase inhibitors
Resistance to the neuraminidase inhibitors oseltamivir
and zanamivir following EMA and FDA approval occurred
only sporadically and mostly on clinical trials in immuno-
compromised patients. The incidence of oseltamivir resis-
tant influenza A(H3N2) and A(H1N1) viruses seen in
clinical trial samples of immunocompetent patients until
July 2004 was 0.33% (4/1228) in adults (≥13 years) and
4% (17/421) in children (≤12 years), resulting in an
overall incidence of 1.26% [67], [68]. An high degree of
A(H1N1) and A(H3N2) oseltamivir-resistant viruses has
been found within two clinical trials [67], [69]. During
oseltamivir treatment about 16.3% (7/43) resistant
A(H1N1) and 18% (9/59) resistant A(H3N2) viruses oc-
curred, which was may be connected to an insufficient
dosage regime.
In contrast to these clinical findings, the occurrence and
spread of neuraminidase inhibitor-resistant strains within
seasonal influenza viruses was a rare event until winter
2007. In comparison to sensitive viruses the resistant
viruses showed a diminished viral fitness, marked by
worse replication rates, and lower transmissibility, leading
to the conclusion that resistance-associated mutations
are unlikely to be of clinical consequence [46], [70], [71].
Therefore, the detection and rapid spread of oseltamivir-
resistant A/Brisbane/59/2007-like A(H1N1) viruses in
November 2007 within the seasonally circulating influ-
enza viruses was unpredicted and unexpected [72]. All
resistant viruses carried the H275Y (histidine-to-tyrosine)
substitution in their neuraminidase and showed highly
reduced susceptibility to oseltamivir. During the following
season 2007–2008 these viruses spread rapidly over
the northern hemisphere. The resistance to oseltamivir
could not be explained with reassortment and was not
the consequence of widespread therapeutically usage of
oseltamivir [73], [74]. The infected patients were not
linked epidemiologically and showed symptoms that were
similar to that of infections with sensitive viruses [75],
[76]. The oseltamivir-resistant viruses were shed by adults
up to eight days and were transmissible by household
contacts without any change in their resistance profile
[76]. They did not show obvious attenuation relative to
earlier viruses carrying the H275Y substitution [77].
During the summer 2008 the prevalence of oseltamivir-
resistant A(H1N1) viruses increased up to 80%within the
southern hemisphere. In the following season 2008–
2009 almost all circulating A(H1N1) viruseswere oseltam-
ivir-resistant [78], [79]. Bloom et al. showed that two
permissive secondary mutations (V234M, R222Q) oc-
curred in seasonal A(H1N1) shortly before the widespread
appearance of H275Y. These mutations restore the det-
rimental influence of the NA-H275Y mutation and thus
enable the evolution of influenza oseltamivir resistance
[80].
In 2009, a triple reassortant swine virus reassorted with
an Eurasian avian-like swine virus resulting in the
A(H1N1)pdm09 virus, that has spread internationally with
unprecedented speed and caused the first pandemic of
the 21st century [64], [78], [81]. The A(H1N1)pdm09
neuraminidase originated from the Eurasian avian-like
swine A(H1N1) virus and is characterized by neuramini-
dase inhibitor sensitivity [64]. The former oseltamivir-
resistant seasonal A(H1N1) virus become to extinct soon
after the emergence of the A(H1N1)pdm09 virus [78].
In Germany, overall 3,720 influenza viruses (66%
A(H1N1)pdm09, 19% A(H3N2) and 15% influenza B) cir-
culating between April 2009 andMay 2016were analyzed
phenotypically and/or genotypically [82]. Only twelve out
of 2,430 A(H1N1)pdm09 viruses showed highly reduced
susceptibility to the neuraminidase inhibitor oseltamivir
indicated by an up to 1,000-fold increase of the IC50 for
oseltamivir in phenotypic assays compared to the sensi-
tive wild-type virus. All these resistant viruses carried the
substitution H275Y in their neuraminidase and remained
sensitive to zanamivir. Almost all viruses were collected
from patients during or after oseltamivir treatment. Only,
two pandemic viruses showed resistance to oseltamivir
despite the lack of any evidence that they arose during
antiviral treatment. In the first case, the virus was isolated
from a respiratory sample of a 21-year-old man who de-
veloped an influenza-like illness while staying abroad for
vacation. The second case was a 9-year-old otherwise
healthy boy. The oseltamivir-resistance was confirmed
by phenotypic analysis of the virus isolates. Pyrosequen-
cing analysis performed on the patients’ respiratory spe-
cimens showed the molecular resistance marker NA-
H275Y. In both cases the viruses remained sensitive to
zanamivir in phenotypic assays with IC50<2nMand further
molecular markers of resistance in viral NAs were not
detected [42], [62], [83]. A(H3N2) viruses with altered
susceptibility to neuraminidase inhibitors were detected
in two cases. In 2012 treatment-selected A(H3N2) viruses
showing reduced susceptibility to neuraminidase inhibi-
tors due to the NA-R292K substitution were isolated from
two children at day five of oseltamivir treatment [84]. In-
fluenza B viruses showing reduced susceptibility to
neuraminidase inhibitors were not detected.
Globally, about 99% of the tested influenza viruses were
susceptible against the four neuraminidase inhibitors.
The prevalence of viruses with reduced or highly reduced
sensitivity to neuraminidase inhibitors was highest with
1.9% in the 2013–2014 influenza season, compared to
the 2012–2013 and 2014–2015 seasons where the
frequencies were 0.6% and 0.5%, respectively [85]. The
increase of resistant viruses in 2013–2014 is associated
with the detection of several clusters of A(H1N1)pdm09
viruses carrying the H275Y substitution in China, Japan
and the United States [86]. In A(H3N2) and influenza B
viruses,mutations, known to confer reduced susceptibility
to neuraminidase inhibitors or phenotypically reduced
sensitivity are being detected at a substantially lower
frequency than in A(H1N1)pdm09 viruses [78].
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8 Conclusions
Influenza virus infection is a serious and frequently under-
estimated disease. Due to the development of adaman-
tane resistance in A(H3N2) and the emergence of ada-
mantane-resistant A(H1N1)pdm09 viruses in 2009, the
neuraminidase inhibitors zanamivir and oseltamivir are
the only effective antiviral drugs, available commercially
in Europe. They act against all of the currently circulating
human influenza viruses. Although reduced susceptibility
to these antivirals remains rare, the appearance and
spread of resistant viruses in the past underlines the ur-
gent need to develop and/or approve new active com-
pounds and to closely monitor the resistance profiles of
circulating influenza viruses in the international context.
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